Jon Stonehouse: Yes. I think the other thing, Justin, is that there are docs out there that they are patients controlled, and that’s good enough for them. And so what we’ve got to be able to do is say, no, a patient could do a whole lot better in terms of burden of therapy if they want to a once-daily oral and to dip away at that. And I think part of Charlie’s expansion, where we’re having the regional business directors focus on KOLs is to get those potential high prescribers to start to break through even further, get the ones that haven’t prescribing the ones that have to prescribe more.
Justin Kim: I guess, I am just curious in terms of your views on the long-term growth trajectory, is that mix of where the strip is coming from expected to change, whether between the 500 and non-500 base? I mean just trying to understand if that split of 50-50 is expected to continue and then for how long?
Charlie Gayer: I think it’s a good question. First of all, I am really happy with that balance because what it shows is that we are reaching all parts of the market, and we are growing in both segments. So, we are we’re constantly expanding the number of top 500 doctors who are new ORLADEYO prescribers, and then we are seeing them once they do, go deeper into their list and then that next thousands or so doctors were expanding it to them as well. So, there is €“ what it tells me is there is a lot of opportunity left in front of us, both amongst what HCPs can do and then the number of patients that can €“ that still haven’t experienced the benefit of ORLADEYO. And our goal long term is to give every patient who needs to be on prophylaxis, a chance to try ORLADEYO because most of them are going to do really well.
Jon Stonehouse: Yes. And I think there is two really interesting pieces of evidence that we are going in that direction to. One is quarter-to-quarter, we are expanding the prescriber base and the second is the market research quarter-after-quarter-after-quarter says that docs are going to prescribe more in 12 months than they are currently prescribing. And that’s the combination of people who have not yet prescribed that will in the future or those that are prescribing that will prescribe more. So, those we think are two really encouraging pieces of data that give us a lot of confidence it’s going to keep growing.
Justin Kim: Great. Thanks so much.
Jon Stonehouse: You’re welcome.
Operator: The next question comes from Brian Abrahams of RBC Capital Markets. Please go ahead.
Brian Abrahams: Hi. Good morning. Thanks for taking my questions. You guys have talked about a recent slower conversion from free drug to pay commercial drug in fourth quarter. And I just want to better understand this trend. Do you think this is reflecting just expanding to new physicians who may be less used to prescribing ORLADEYO? And are there ways to help educate those physicians about how to process the necessary paperwork, or is there anything different about these patients, either they have milder disease or more on prior prophylaxis or have different types of insurance plans that may be contributing to this greater lag time? And then just real quick on 10013, were the preclinical findings you observed shared with relevant regulators? And is there any need to, I guess pause dosing, or should we just expect you will be looking at shorter durations and/or lower dose levels as the clinical studies proceed. Thanks.
